Tuesday, January 19, 2021
Home Latest News CiSTEM develops various cell therapy products using induced pluripotent stem cells

[19th MIK 2020 SEASON OFF ONLINE] CiSTEM develops various cell therapy products using induced pluripotent stem cells

CiSTEM is participating in the 19th MIK 2020 SEASON OFF ONLINE ZOOM event on Dec. 8, 4:00 pm as a part of KHIDI project.

Various disease models using induced pluripotent stem cells

Using a next-generation stem cell technology called induced pluripotent stem cells, it produces stem cell lines derived from normal people and patients, provides disease modeling platform services that can replace animal experiments, and develops stem cell-based therapeutics. It is a biotechnology company that is building a diverse diagnostic and therapeutic pipeline.

The company staff said, “In general, induced pluripotent stem cells are cells that are not much known compared to various stem cells such as embryonic stem cells, mesenchymal stem cells, and fat stem cells, and it is the next generation that can solve various problems of existing stem cells. Like embryonic stem cells, it has the ability for self-renewal, so there is no limit on the number of cells, and it has pluripotency and can differentiate into all kinds of somatic cells. Also, because induced pluripotent stem cells are produced by dedifferentiating from readily available blood or skin cells, they are free from social and ethical problems of embryonic stem cells made from fertilized eggs, and it can solve the difficulties in cell culturing and restriction in differentiation which the adult stem cells (mesenchymal stem cells, adipocyte stem cells, etc.) have.”

Cell therapy using induced pluripotent stem cells

Regarding the future business plan, “As a strategic investment with pharmaceutical companies related to the development of cartilage cell therapy products, we plan to sell and distribute products to five countries at home and abroad. By utilizing and developing our own technologies, we will develop various cell therapy products using induced pluripotent stem cells and build diverse disease modeling platform that can replace animal testing in pharmaceutical or cosmetic companies to provide the testing service.”

He then said, “Furthermore, we are in the process of applying for and registering overseas patents for our technologies to enter the overseas market. We are also participating in various exhibitions, seminars, and corporate IRs conducted overseas to establish an overseas network, and would like to incorporate overseas and expand globally.”


Cartilage regeneration treatment prototypes and efficacy evaluation in critical animals

The 19th MIK 2020 SEASON OFF ONLINE is hosted by AVING NEW,S the media partner of more than 100 trade shows including MWC and IFA that has established a global news network with major media companies in 54 countries. This time, seven media, Vietnamplus from Vietnam, Myfatpocket from Singapore, Geekazine from the US, SINA from China, LeCafeduGeek from France, IT DONGA from Korea, SVPRESSA.RU from Russia, and STARTUPWORLD.TECH from France will be participating to publicize the participants to the world.

In this event, 24 companies will participate with support from Korea Health Industry Development Institute (KHIDI), Gwangju Information & Culture Industry Promotion Agency (GITCT), Daejeon Information & Culture Industry Promotion Agency (DICIA), Seoul Startup Hub Seongsu, and Twosun Campus. △IBS Tech △Awesomepia △BA Energy △CiSTEM △Biotruss △Wellmarker Bio △CM Lab △Cell2in △SKIMS-Bio △Caredoc △LiBEST △THE.WAVE.TALK △Dotrade △Linkoptics △Geniesoft △Ghost Pass △SafeTech Research △Myung Kwang Chemical △Multics △Batoners △THES △J2 △Myungsung Corporation △Baice

→ Go to 19th MIK 2020 SEASON OFF ONLINE news page

- Advertisment -

Most Popular

Recent Comments